Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.

Červinek L, Černá O, Čaniga M, Konířová E, Hluší A, Šimkovič M, Pospíšil Z, Čermák J, Kozák T, Mayer J, Doubek M.

Int J Hematol. 2012 Nov;96(5):594-9. doi: 10.1007/s12185-012-1206-7. Epub 2012 Oct 26.

PMID:
23099924
[PubMed - indexed for MEDLINE]
2.

Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.

Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.

J Intern Med. 2009 Nov;266(5):484-91. doi: 10.1111/j.1365-2796.2009.02126.x. Epub 2009 Apr 27.

PMID:
19549092
[PubMed - indexed for MEDLINE]
3.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.

Am J Hematol. 2005 Apr;78(4):275-80.

PMID:
15795920
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.

Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand JM, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, Godeau B, Michel M.

Am J Hematol. 2013 Oct;88(10):858-61. doi: 10.1002/ajh.23518. Epub 2013 Sep 3.

PMID:
23798363
[PubMed - indexed for MEDLINE]
5.

Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.

Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.

Am J Hematol. 2012 Sep;87(9):886-9. doi: 10.1002/ajh.23272. Epub 2012 Jun 20.

PMID:
22718483
[PubMed - indexed for MEDLINE]
6.

Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.

Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, Jean R, Kaplanski G, Harlé JR, Durand JM.

Ann Hematol. 2012 Feb;91(2):279-85. doi: 10.1007/s00277-011-1283-3. Epub 2011 Jun 28.

PMID:
21710166
[PubMed - indexed for MEDLINE]
7.

Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.

Auger S, Duny Y, Rossi JF, Quittet P.

Br J Haematol. 2012 Aug;158(3):386-98. doi: 10.1111/j.1365-2141.2012.09169.x. Epub 2012 May 22.

PMID:
22612239
[PubMed - indexed for MEDLINE]
8.

Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.

Schweizer C, Reu FJ, Ho AD, Hensel M.

Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.

PMID:
17622529
[PubMed - indexed for MEDLINE]
9.

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.

Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.

Am J Ther. 2013 Mar-Apr;20(2):219-22. doi: 10.1097/MJT.0b013e318258905e.

PMID:
23466621
[PubMed - indexed for MEDLINE]
10.

Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J; Mexican Hematology Study Group.

Ann Hematol. 2007 Dec;86(12):871-7. Epub 2007 Sep 14.

PMID:
17874322
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Rituximab for children with immune thrombocytopenia: a systematic review.

Liang Y, Zhang L, Gao J, Hu D, Ai Y.

PLoS One. 2012;7(5):e36698. doi: 10.1371/journal.pone.0036698. Epub 2012 May 30. Review.

PMID:
22666325
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.

Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Sánchez-Cárdenas M.

Eur J Haematol. 2013 Jun;90(6):494-500. doi: 10.1111/ejh.12102. Epub 2013 Apr 2.

PMID:
23470153
[PubMed - indexed for MEDLINE]
13.

Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.

D'Arena G, Capalbo S, Laurenti L, Del Poeta G, Nunziata G, Deaglio S, Spinosa G, Tarnani M, De Padua L, Califano C, Ferrara F, Cascavilla N.

Eur J Haematol. 2010 Dec;85(6):502-7. doi: 10.1111/j.1600-0609.2010.01527.x. Epub 2010 Nov 8.

PMID:
20846302
[PubMed - indexed for MEDLINE]
14.

[Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].

Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.

Zhonghua Xue Ye Xue Za Zhi. 2011 Mar;32(3):163-7. Chinese.

PMID:
21535953
[PubMed - indexed for MEDLINE]
Free Article
15.

[Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].

Zhou LY, Zhang Z, Song LX, Gzhang X, Su JY, Li X, Chang CK.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):941-4. Chinese.

PMID:
22931660
[PubMed - indexed for MEDLINE]
16.

Low-dose rituximab in adult patients with primary immune thrombocytopenia.

Zaja F, Vianelli N, Volpetti S, Battista ML, Defina M, Palmieri S, Bocchia M, Medeot M, De Luca S, Ferrara F, Isola M, Baccarani M, Fanin R.

Eur J Haematol. 2010 Oct;85(4):329-34. doi: 10.1111/j.1600-0609.2010.01486.x. Epub 2010 Jul 28.

PMID:
20546023
[PubMed - indexed for MEDLINE]
17.

Treatment of chronic immune thrombocytopenic purpura with rituximab in children.

Dogan M, Oner AF, Acikgoz M, Uner A.

Indian J Pediatr. 2009 Nov;76(11):1141-4.

PMID:
20092026
[PubMed - indexed for MEDLINE]
18.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR; Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP.

Ann Hematol. 2006 Jun;85(6):400-6. Epub 2006 Mar 21. Erratum in: Ann Hematol. 2006 Aug;85(8):558. Dosage error in article text.

PMID:
16550390
[PubMed - indexed for MEDLINE]
19.

Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.

Aleem A, Alaskar AS, Algahtani F, Rather M, Almahayni MH, Al-Momen A.

Int J Hematol. 2010 Sep;92(2):283-8. doi: 10.1007/s12185-010-0635-4. Epub 2010 Jul 17.

PMID:
20640541
[PubMed - indexed for MEDLINE]
20.

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.

Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB.

Blood. 2012 Jun 21;119(25):5989-95. doi: 10.1182/blood-2011-11-393975. Epub 2012 May 7.

PMID:
22566601
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk